Express Scripts Leads Industry with New HIV Prevention Program

The HIV Care Value^SM program, part of the company’s SafeGuardRx® platform, will drive value and improve cost predictability for employers, health plans, and people at risk for HIV.

HIV Care Value Program: Prevention and Predictability

Our new industry-first HIV Care Value^SM program, part of the SafeGuardRx® platform, will drive value and improve cost predictability for employers, health plans, and people at risk for HIV.

National Preferred Formulary: Access Meets Value in HIV Treatment

Our National Preferred Formulary continues to deliver savings with minimal member impact, leading to more favorable medication adherence.

FDA Approved Drugs: August 2020

The Express Scripts Office of Clinical Evaluation and Policy lists the drugs that were approved by the Food and Drug Administration (FDA) in July 2020. (Estimated Reading Time: ~10 mins.)

An Affordable Alternative for Daraprim: $1 per Pill

Express Scripts and Imprimis Pharmaceuticals champion the needs of patients who can't pay $750 for a single pill.

ScreenRx: The Cure for the Costliest Health Care Problem

To date, ScreenRx has closed 37% of medication adherence gaps and has recorded $188.6 million in total healthcare savings for our clients.

Hemophilia: Accredo Simplifies Complex Care

Accredo website helps both patients living with bleeding disorders and their health care providers manage a complex disease.

INFOGRAPHIC: The Big Numbers Driven by Specialized Care

Our Therapeutic Resource Centers^SM provide disease-specific clinical care – with a 98% patient satisfaction rate from 30 million annual interactions and 4.8 million gaps in care addressed.

Uncovering Prescription Drug Fraud, Waste, and Abuse during COVID-19

New research shows that every $1 of fraud, waste, or abuse costs $66 in related expenses. This is true even during a pandemic.

FDA Approved Drugs: October 2019

The Express Scripts Office of Clinical Evaluation and Policy tracks some recent updates to the drug pipeline.

FDA Approved Drugs: December 2019

The Express Scripts Office of Clinical Evaluation and Policy tracks some recent updates to the drug pipeline.

A Pharmacist Can Change One Life – And a Million

Every day, hundreds of pharmacists across Express Scripts are working to improve health for individual patients as well as nationwide patient populations.

FDA Approved Drugs: November 2019

The Express Scripts Office of Clinical Evaluation and Policy tracks some recent updates to the drug pipeline.

FDA Approved Drugs: September 2020

The Express Scripts Office of Clinical Evaluation and Policy lists the drugs that were approved by the Food and Drug Administration (FDA) in August 2020. (Estimated Reading Time: ~10 mins.)

How Getting Your Flu Shot Helps the Fight Against COVID-19

Across a divided and suffering America, many of us are united by hope for a safe and effective COVID-19 vaccine in the coming months. However, as individuals, we should get our flu shots as soon as we...

FDA Approved Drugs: October 2020

The Express Scripts Office of Clinical Evaluation and Policy tracks some recent updates to the drug pipeline.

2019 National Preferred Formulary: Better Access. Better Value.

Our National Preferred Formulary will provide payers and their members access to 3,886 medications while saving $3.2 billion on their prescription drug bill.

Viral Signs: Understanding HIV Medication Use

Our latest research report reveals increased use of single-tablet HIV regimens can yield lower costs and better outcomes; underscores need to expand affordable access to PrEP.

FDA Approved Drugs: March 2020

The Express Scripts Office of Clinical Evaluation and Policy tracks some recent updates to the drug pipeline.

Managing Complex & Chronic Disease

Creating a stronger future with SMART Coalition

Improving Health

Innovating For Better: 30+ Years and Counting

From the beginning, our members have been our focus. On their behalf, we’ve acted first to tackle the toughest challenges in health care, even when we acted alone. And we’re just getting started.

Edward Dannemiller, RPh